letetresgene autoleucel 
gsk
['sarcoma']
lete-cel demonstrated anti-tumor activity with a tolerable safety profile in patients with advanced and metastatic myxoid/round cell liposarcoma (mrcls), according to data from a phase 2, open-label study (nct02992743). #asco22 
CGTLive™ delivers quality and relevant information to healthcare professionals on cell, gene, regenerative, and engineered medicines to ultimately improve care.